Rozerem

Quick links to important sections

Rozerem

Treatment option: Insomnia

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Rozerem

Rozerem is the trade name for the prescription medicine that contains the single active ingredient, Ramelteon. This unique synthetic compound is classified pharmacologically as a Melatonin Receptor Agonist, belonging to a distinct class of sedative-hypnotic agents. Its primary objective is to address insomnia characterized by difficulty with sleep onset in adults. Rozerem is a prescription-only medication developed and initially marketed by Takeda Pharmaceutical Company.


Quick Facts

Property Description
Active ingredient Ramelteon
Form Oral tablet
Pharmacological class Melatonin Receptor Agonist
Origin Synthetic compound
General use Promoting sleep onset

Ramelteon: Definition and Pharmacological Classification

Ramelteon is a synthetic drug that acts as a highly selective agonist for the MT₁ and MT₂ melatonin receptors, which are primarily located in the brain's suprachiasmatic nucleus (SCN). The mechanism is clinically recognized for selectively reinforcing the body's internal clock without the broad actions of traditional sedatives.

This targeted mechanism distinguishes Ramelteon from older, non-selective sedative-hypnotic agents. Unlike many traditional hypnotics, it has demonstrated no appreciable affinity for central nervous system (CNS) receptors associated with generalized sedation, such as the GABAₐ receptor complex. This focused activity led to its classification as a chronobiotic agent, meaning its primary function is to adjust the timing of the sleep cycle rather than to induce general CNS depression.


Rozerem Form and Core Function

The medication is composed of the active compound Ramelteon and necessary pharmaceutical excipients formulated into an immediate-release oral tablet. The standard strength for the Rozerem tablet is 8 mg. This systemic administration delivers the compound to the brain to promote sleepiness.

The core function of Ramelteon is to promote the process of sleep onset by mimicking the signaling effect of the naturally occurring hormone melatonin. This action supports the initiation of sleep, making its general purpose linked to facilitating the transition from wakefulness to sleep. This unique profile of selective receptor targeting is a key differentiating factor from other sleep medications.

What side effects are possible with Rozerem?

Possible Side Effects and Safety Information

This section describes the officially documented adverse reactions and safety characteristics of ramelteon (Rozerem) as defined in government regulatory labeling.

Common and Expected Adverse Reactions

The most frequently reported adverse reactions, classified as common based on clinical trial data, primarily involve the Nervous System and general physical state. These include somnolence (drowsiness), dizziness, and fatigue. Other common reactions listed in regulatory documents include nausea and the worsening of insomnia.


Serious Safety Considerations

Official labeling documents address several serious and clinically significant safety concerns:

  • Complex Sleep Behaviors: Events such as "sleep-driving," preparing food, or making phone calls while not fully awake, often accompanied by amnesia for the event, have been reported and require specific regulatory warnings.
  • Severe Allergic Reactions: Rare cases of anaphylaxis and angioedema (swelling of the face, tongue, or throat), which can be life-threatening due to potential airway obstruction, are documented.
  • Psychiatric Effects: The potential for the emergence or worsening of depression and related suicidal ideation is noted, as observed with other hypnotic agents.
  • Hormonal Changes: Ramelteon has been associated with changes in hormone levels, specifically decreases in testosterone and increases in prolactin, which may lead to effects on the reproductive system.

Safety Restrictions and Contraindications

The medicine is not recommended for use in patients with severe hepatic impairment (liver disease) or severe obstructive sleep apnea. Ramelteon is contraindicated (should not be used) in combination with fluvoxamine due to significant drug exposure increase. Safety and effectiveness have not been established for use in patients younger than 18 years of age.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for Ramelteon (Rozerem) overdose states that manifestations are primarily expected to be extensions of the drug’s pharmacological effects. These documented clinical presentations include pronounced somnolence and fatigue. Overdose scenarios may also involve the emergence of abnormal thinking and complex sleep behaviors, such as sleep-driving or making phone calls, with subsequent amnesia for the event.

Documented Severe Outcomes

A critical, life-threatening risk documented in regulatory warnings is the potential for severe anaphylactic reactions and angioedema, specifically involving the swelling of the tongue, glottis, or larynx. This condition can lead to airway obstruction, which may result in a fatal outcome.

Required Emergency Action

In the event of suspected overdose or the onset of severe allergic symptoms, official guidance requires the patient or caregiver to seek emergency medical attention immediately and to contact a Poison Control Center right away. Urgent medical help is mandatory when signs of a severe allergic reaction (e.g., swelling, difficult breathing) are present.

Management and Considerations

Overdose management is carried out using general symptomatic and supportive measures. The official label confirms that no specific antidote for Ramelteon is known. Additionally, Ramelteon is not recommended for use in patients with severe hepatic impairment, as this population may experience increased systemic exposure.

Therapeutic Uses of Rozerem

What Rozerem Treats: Main Uses and Benefits

The medication is commonly used to address insomnia characterized by difficulty with sleep onset, a therapeutic domain relevant for adult patients. It is applied when patients experience chronic or transient episodes where the main difficulty is the prolonged time to fall asleep (high sleep latency). The primary therapeutic benefit assists the patient with initiating the rest cycle.


Supportive Management for Symptoms of Sleeplessness

Rozerem is generally applied across the adult and geriatric patient populations in situations where symptoms of sleeplessness, such as the persistent inability to begin resting, create noticeable interference with daily comfort. The therapeutic use offers support that helps ease the overall burden of symptoms, which contributes to assisting with the transition into sleep and supports general well-being during symptomatic phases.


Quick Fact: Use for Sleep Onset Difficulty

The medicine is used to help manage symptoms related to difficulty initiating sleep and prolonged sleep latency in adults.

Regulatory References

  1. MedlinePlus Drug Information overview

Eligibility and Restrictions for Use

Rozerem (ramelteon) is approved for use in adults (18 years of age and older). Official regulatory documentation defines several specific exclusions and restrictions on who may take this medicine.

Contraindications and Restrictions

Contraindicated Populations (Must Not Use)

Classification Population/Condition
Prior Hypersensitivity Patients with a history of angioedema (severe allergic reaction with swelling) after taking ramelteon.
Drug Interaction Patients currently taking fluvoxamine (a strong CYP1A2 inhibitor).

Use Not Recommended

Classification Population/Condition
Hepatic Impairment Patients with severe hepatic impairment (liver disease/Child-Pugh Class C).
Sleep Disorder Patients with severe obstructive sleep apnea (use is not established in this population).

Age and Physiological Status

The safety and effectiveness of Rozerem have not been established in pediatric patients (less than 18 years of age). In the context of pregnancy, Rozerem is classified as Pregnancy Category C, and its use during lactation should be considered with caution.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Ramelteon (Rozerem) is defined by its pharmacokinetic metabolism and potential for pharmacodynamic additive effects, as outlined in regulatory documentation.

Documented Interaction Restrictions

Co-administration with Fluvoxamine is formally contraindicated by regulatory agencies. This restriction is due to Fluvoxamine's potent inhibition of the CYP1A2 enzyme, which dramatically increases the systemic exposure (AUC) of Ramelteon.

Pharmacokinetic and Pharmacodynamic Interactions

Interacting Substance/Class Official Interaction Pattern
Strong CYP Inhibitors Co-administration with Ketoconazole ( CYP3A4 inhibitor) and Fluconazole ( CYP2C9 inhibitor) increases Ramelteon systemic exposure. Cautious use is officially noted.
CNS Depressants Alcohol (ethanol) and other CNS depressants may result in additive effects, specifically additive psychomotor impairment.
CYP Inducers The CYP inducer Rifampin is documented as expected to decrease the exposure of Ramelteon.

Administration and Population Constraints

Food: Ramelteon must not be taken with or immediately after a high-fat meal, as this drug–food interaction significantly increases the amount of medicine absorbed into the blood.

Population: The medicine is not recommended in patients with severe hepatic impairment, as reduced drug clearance in this population leads to heightened systemic exposure and increased risk of interaction effects. Ramelteon should not be used in combination with alcohol.

Mechanism of Action

Melatonin Receptor Agonism

Ramelteon functions as a selective agonist at the MT1 and MT2 melatonin receptors in the central nervous system. This direct binding mimics the action of endogenous melatonin, initiating a signaling cascade that mediates the acute inhibition of SCN neuron firing.


Targeting the Suprachiasmatic Nucleus (SCN)

The compound's primary activity location is the Suprachiasmatic Nucleus (SCN) in the hypothalamus, the central regulator of the 24-hour rhythmic processes (circadian rhythm). Activation of MT1 and MT2 receptors on SCN neurons regulates the phase-shifting effects associated with circadian signal transduction.


Modulation of Neuronal Electrical Activity

This action is distinct from mechanisms involving GABA receptor modulation. The mechanistic effect involves amplification of melatonergic signal transduction within the SCN, resulting in a decrease in SCN neuronal electrical activity and the corresponding modulation of the sleep-wake cycle.

Dosage and Administration Information

Administration and Dosing of Rozerem

The prescription medication Rozerem, which contains the active ingredient ramelteon, is provided exclusively as an 8 mg immediate-release tablet for oral administration. The usage protocol is defined by a strict, non-titratable dosing pattern designed to align with the initiation of the sleep cycle.

Dosing Parameter Official Guideline
Dose and Frequency Single 8 mg dose, once daily; do not exceed 8 mg per day.
Timing Administer within 30 minutes of going to bed when the patient is ready to initiate sleep.
Food Constraint Should not be taken with or immediately after a high-fat meal.

Use Contexts and Population Guidelines

Proper use of ramelteon involves specific administration constraints and population-based rules. Following the dose, the patient's activities must be limited strictly to those necessary for preparing for bed. This ensures the medication's effect is optimally timed for sleep onset.

Regarding specific patient populations, no dose adjustment is required for any degree of renal impairment. However, the use of ramelteon is not recommended for patients with severe hepatic impairment. While approved for the adult population and suitable for long-term use in managing sleep onset difficulty, the safety and effectiveness have not been established in pediatric patients.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Rozerem


Evidence for Difficulty Falling Asleep (Sleep Onset Insomnia)

Research has studied Rozerem for its relevance in trials assessing short-term or episodic symptom patterns related to difficulty falling asleep. These studies typically focused on outcomes reflecting daily functioning or activity level, specifically measuring sleep latency, including how quickly people were able to achieve sleep after taking the medication in the studies, and how these studies were conducted.

Studies in this area have examined populations experiencing conditions characterized by fluctuating or episodic manifestations of sleep problems. Findings describe patterns observed in the studies over short time intervals, often lasting a few weeks, and these findings describe patterns observed in how patients reported their experience regarding the time it took to fall asleep. However, it is important to remember that study results reflect the specific conditions under which they were conducted, and research does not determine whether an individual will respond similarly.


Evidence for Maintaining Sleep Throughout the Night

Research also evaluated Rozerem in the context of helping people stay asleep, exploring outcomes describing episodic or acute changes in sleep patterns. Studies in this area explored whether the use of this medication may assess changes in how often people woke up during the night and the total amount of sleep measured. These investigations often involve outcomes related to systemic or functional imbalance and use specialized monitoring in controlled settings.

Findings were mixed regarding Rozerem's relevance to these sleep maintenance measures. While some research suggests certain changes were observed in some studies during the defined time intervals, other studies show patterns related to this area were less pronounced. Evidence highlights what is known—and what is still uncertain—about the medication's studied outcomes for individuals who struggle with waking up frequently after initially falling asleep.


Long-term Studies and Follow-up

Research has explored the outcomes observed when Rozerem was studied during periods extending beyond the short-term trials, particularly in conditions where symptoms may vary in intensity over many months. This area of evidence was studied for long-term patterns of sleep measures over time, looking at whether any observed patterns continue with extended use.

However, follow-up durations were limited in many studies, meaning that long-term effects are not fully established. There is limited information for long-term outcomes regarding the continued use of Rozerem. Data are still emerging, and this evidence gap highlights a key area where more research is ongoing to fully understand the long-term patterns associated with this medication.


Evidence in Special Populations

Specific research was observed in certain groups of patients, such as older adults. For these special populations, studies examined if the observed patterns of change in falling asleep were consistent with those seen in the general study population. This research is relevant in trials assessing short-term or episodic symptom patterns in people who may have additional medical considerations.

Data regarding other groups, such as those with certain comorbid conditions or those who are pregnant, data for certain groups remain insufficient. Also, for children and adolescents, the evidence was studied for but certainty remains low due to limited patient numbers and research duration. Results apply only to the populations studied, and the evidence quality varies across studies when looking at these distinct patient groups.


What is Still Uncertain About Rozerem

Research has provided information about how Rozerem was observed in studies related to sleep onset, but there are areas where more research is needed. One area of uncertainty involves the comparisons of studied outcomes when evaluated directly against other therapies for sleep difficulties; this is because comparative evidence is lacking or evidence quality varies across studies.

Additionally, some subgroup findings are uncertain, especially when looking at individuals with conditions involving periods of heightened symptoms that are not specifically sleep-related. The findings describe patterns observed in how patients reported their experience within the study setting, but the main evidence gap is the lack of robust, long-duration data. Evidence is limited for long-term use, and this remains a crucial area for future research to address.

Key Studies & References Ramelteon in the treatment of chronic insomnia: systematic review and meta-analysis (Liu J, Wang LN, 2012)

Frequently Asked Questions (FAQ)

Common questions about Rozerem (FAQ)

Q: Does Rozerem make you feel groggy or tired the next morning?

A: According to official product information, ramelteon can potentially affect a person's alertness or coordination even the day after it is taken. Patients are cautioned in the labeling to avoid activities that require full concentration, such as driving or operating heavy machinery, until they are fully awake and understand how the medication affects them.

Q: What's the main difference between Rozerem and a benzodiazepine like Ambien?

A: The key difference lies in the mechanism of action. Rozerem works by targeting melatonin receptors in the brain, mimicking the body's natural sleep signals. Unlike traditional sedative hypnotics, official information notes that Rozerem does not act on the GABA receptor complex, which is the system that causes generalized sedation.

Q: Does Rozerem have a risk of addiction or withdrawal symptoms?

A: Regulatory documents state that ramelteon has not been shown to produce dependence or abuse potential in clinical studies, and it is not classified as a controlled substance.

Q: Can people with depression or anxiety safely use Rozerem?

A: Official labeling notes that the potential for worsening depression and suicidal ideation has been reported with hypnotics, including ramelteon. Patients are generally advised that ramelteon is used cautiously in those with a history of depression, and they should be monitored for any changes in mood or behavior.

Q: Is Rozerem primarily used for falling asleep or for staying asleep?

A: Ramelteon is officially indicated for treating insomnia that is characterized by difficulty with sleep onset (falling asleep). It is not specifically indicated in official labeling for addressing problems with sleep maintenance (staying asleep through the night).

Q: Why is Rozerem sometimes preferred for people with a history of substance abuse?

A: Official information regarding drug abuse and dependence states that ramelteon has not been shown to produce dependence or abuse potential. Its lack of dependence or abuse potential is a notable characteristic mentioned in official documents.

Q: Is it normal to feel a mild headache when first starting Rozerem?

A: Headache is one of the commonly reported side effects listed in the official documents from clinical trial data, occurring in a small percentage of patients.

Q: Can Rozerem interact with herbal supplements like melatonin or valerian root?

A: Ramelteon is structurally related to the hormone melatonin and acts on the same receptors, suggesting a potential for additive effects if they are taken together. Patients are advised in the labeling to inform their healthcare provider about all supplements, including herbal products, to identify any potential interactions.

Q: Can Rozerem affect hormone levels, especially in women?

A: Official studies indicate ramelteon has been associated with changes in reproductive hormone levels in adults. Specifically, decreases in testosterone and increases in prolactin have been reported.

Q: Are there any known severe or rare side effects associated with Rozerem?

A: Yes, official labeling notes several serious safety concerns. These include the potential for complex sleep behaviors (such as 'sleep-driving' or making phone calls while not fully awake, often followed by amnesia) and rare but serious allergic reactions like anaphylaxis or swelling of the face, tongue, or throat (angioedema).

Q: Can Rozerem be used by teenagers or adolescents with sleep issues?

A: According to the official prescribing information, the safety and effectiveness of ramelteon have not been established in pediatric patients, which includes those younger than 18 years of age.

Q: What kind of research exists on Rozerem use in pregnant or breastfeeding women?

A: Official regulatory information classifies ramelteon as Pregnancy Category C, meaning the risk cannot be ruled out. During lactation, official documents note that interruption of breastfeeding should be considered due to the potential for infant somnolence.

Q: Is it common to forget things or have memory issues on Rozerem?

A: Regulatory warnings describe 'complex sleep behaviors' that have been reported with hypnotics. These events, which include activities performed while not fully awake, are often accompanied by amnesia, meaning the person cannot recall the event afterward.

Q: Is there a generic version of Rozerem available?

A: Ramelteon, the active ingredient in Rozerem, is available as an FDA-approved generic drug.

Q: What is the difference between Rozerem and prescription sleep aids that aren't Z-drugs?

A: Rozerem is a melatonin receptor agonist that works differently than many traditional prescription sleep aids. It is distinguished by its lack of significant action on the CNS receptors associated with generalized sedation, such as the GABA receptors, making its effect more targeted to the sleep-wake cycle.

Q: Can Rozerem cause changes in mood or behavior?

A: Official labeling states that changes in thinking and behavior have been reported in patients taking hypnotics. These changes can include decreased inhibition, aggressiveness, agitation, and hallucinations.

Q: What is the average time it takes for Rozerem to kick in?

A: The official recommendation is to take the dose within 30 minutes of going to bed, implying that the onset of the effect is expected to occur relatively shortly after administration to aid in the initiation of sleep.

Q: Is it normal to feel a bit dizzy or lightheaded when waking up after taking Rozerem?

A: Dizziness is listed in the official adverse reactions table as one of the most frequently reported side effects from clinical trial data. Patients are generally advised to exercise caution when standing or moving if they experience dizziness.

Q: Can Rozerem be taken with over-the-counter pain relievers like Advil or Tylenol?

A: Interactions with over-the-counter pain relievers vary based on the specific ingredients. Official data suggests that the metabolism of ramelteon may be affected by acetaminophen. Official labeling reminds patients to discuss all prescription and nonprescription medicines with a healthcare provider.

Q: Can Rozerem be taken with common allergy medications?

A: Allergy medications, particularly certain antihistamines, can be central nervous system (CNS) depressants that increase drowsiness and dizziness. Because ramelteon can also cause CNS effects, the official information warns that combining it with other CNS depressants may result in additive psychomotor impairment.

Q: Does Rozerem lose its effectiveness if you break or chew the tablet?

A: Ramelteon is provided as an immediate-release tablet for oral administration. To ensure the full dose is received and absorbed as intended, tablets should generally be swallowed whole.

Q: Is it okay to take Rozerem only on certain nights, or does it need to be consistent?

A: The recommended pattern is a single dose, once daily. Since it is approved to treat difficulty with sleep onset, official guidance supports limiting the total daily dose to the amount prescribed and taking it when needed to initiate sleep.

Q: Is Rozerem safe to take every single night long-term?

A: Ramelteon is officially approved for the treatment of insomnia and is suitable for long-term use in adults who experience difficulty falling asleep.

Q: What is the maximum amount of time Rozerem can be safely used?

A: The medication is approved for the long-term treatment of sleep onset insomnia. The official labeling does not specify an absolute maximum time limit for safe use.

Q: What should I avoid doing right after taking Rozerem?

A: Official guidance emphasizes that activities should be strictly limited to those necessary to prepare for bed after taking the dose. The labeling advises against engaging in hazardous activities that require concentration until you are fully awake.

How should Rozerem be stored and disposed of?

How to Store and Dispose of Rozerem?

Storage Requirements

Rozerem (ramelteon) tablets must be maintained at controlled room temperature, specifically within the range of 15 C to 30 C (59 F to 86 F). The product must be stored in its original container, which should be kept tightly closed to ensure stability. Official labeling also requires protection from light and moisture and prohibits freezing. For safety, the medication must be stored out of the sight and reach of children.


Disposal Instructions

Unused or expired Rozerem must be disposed of according to official regulatory guidelines. The preferred method is through an established drug take-back program. If a take-back program is not available, the tablets should be mixed with an undesirable substance, sealed in a container or bag, and placed into the household trash. The medication should not be flushed down a toilet unless explicitly instructed by a regulatory body.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Rozerem found in:

A-Z Index: